Multistage delivery of chemotherapeutic nanoparticles for breast cancer treatment

Elvin Blanco, Takafumi Sangai, Angela Hsiao, Silvia Ferrati, Litao Bai, Xuewu Liu, Funda Meric-Bernstam, Mauro Ferrari

Research output: Contribution to journalArticlepeer-review

60 Scopus citations


Adequate drug delivery to tumors is hindered by barriers such as degradation and non-specific distribution. Nested incorporation of drug-containing nanoparticles within mesoporous silicon particles (MSVs), carriers rationally designed to enhance tumor transport, was hypothesized to result in pronounced and sustained antitumor efficacy. Paclitaxel (PTX)-containing poly(ethylene glycol)-block-poly(ε-caprolactone) (PEG-PCL) polymer micelles were favorably loaded within MSVs, after which drug release was significantly delayed. Antitumor efficacy analyses in mice bearing MDA-MB-468 breast tumors demonstrated significant tumor growth suppression following a single administration. Results highlight effective chemotherapeutic shuttling and site-specific controlled release afforded by MSVs, potentially translating towards improvements in patient outcomes and morbidity.

Original languageEnglish (US)
Pages (from-to)245-252
Number of pages8
JournalCancer Letters
Issue number2
StatePublished - Jul 1 2013


  • Cancer nanomedicine
  • Mesoporous silicon particles
  • Multistage drug delivery
  • Paclitaxel
  • Polymer micelles

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Multistage delivery of chemotherapeutic nanoparticles for breast cancer treatment'. Together they form a unique fingerprint.

Cite this